11.4.1 Corticosteroids
| Topical corticosteroids should normally only be used with expert supervision | |
| GREEN Betamethasone eye/ear/nose drops 0.1% |
| GREEN Betnesol-N® eye/ear/nose drops |
| GREEN Dexamethasone eye drops 0.1 (Maxidex®) |
| GREEN Fluorometholone eye drops 0.1% |
| GREEN Maxitrol® eye drops, eye ointment |
| GREEN Prednisolone eye/ear drops 0.5% |
| GREEN Predsol-N® eye/ear drops |
| AMBER Prednisolone eye drops 1% (forte)(specialist use only) |
| |
| For the treatment of post operative inflammation following ocular surgery in patients who are at risk of corticosteroid |
| induced raised intra-ocular pressure. |
| AMBER Loteprednol drops 0.5% (specialist use only) |
| RED Dexamethasone intravitreal implant 700mcg (specialist use only) |
| (For further information, see NICE TA229) |
| |
| NICE Guidance for the treatment of sight problems caused by diabetic macular oedema |
| NICE TA824* Dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by |
| diabetic macular oedema in adults only if their condition has not responded well enough to, or if they |
| cannot have non-corticosteroid therapy. See full guidance |
| *NICE TA824 updates and replaces NICE TA349 (September 2022( |
| |
RED Dexamethasone intravitreal implant 700mcg (specialist use only) ICS Commissioned, Blueteq required
|
| |
| |
| NICE guidance for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| NICE TA301* Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic |
| macular oedema that is insufficiently responsive to available therapies only if: |
> the implant is to be used in an eye with an intraocular (pseudophakic) lens and
|
| > the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the |
| patient access scheme. |
| *[Rapid review of NICE TA271] |
| RED Fluocinolone acetonide intravitreal implant (Iluvien®) NHS England Commissioned |
| |
| NICE guidance for treating visual impairment due to diabetic macular oedema in adults |
| NICE TA799 Faricimab is recommended as an option for treating visual impairment due to diabetic macular oedema |
| in adults, only if: |
| > the eye has a central retinal thickness of 400 micrometres or more at the start of treatment |
| > the company provides faricimab according to the commercial arrangement |
| RED Faricimab (Vabysmo solution for injection vials) ICB Commissioned [formerly CCG]. Blueteq required |
| |
NICE guidance for treating non-infectious uveitis in adults
|
| NICE TA460 Adalimumab is recommended as an option for treating non-infectious uveitis in the posterior segment |
| of the eye in adults with inadequate response to corticosteroids, only if there is: |
| > active disease (that is, current inflammation in the eye) and |
| > inadequate response or intolerance to immunosuppressants and |
| > systemic disease or both eyes are affected (or 1 eye is affected if the second eye has poor visual acuity) |
| and |
| > worsening vision with a high risk of blindness (for example, risk of blindness that is similar to that seen in |
| people with macular oedema). |
| Dexamethasone intravitreal implant is recommended as an option for treating non-infectious uveitis in the |
posterior segment of the eye in adults, only if there is:
|
| > active disease (that is, current inflammation in the eye) and |
| > worsening vision with a risk of blindness. |
| RED Adalimumab solution for injection NHS England Commissioned |
| RED Dexamethasone intravitreal implant 700mcg (specialist use only) NHS England Commissioned |
| |
| NICE guidance for treating non-infectious uveitis |
NICE TA590 Fluocinolone acetonide intravitreal implant is recommended as an option for preventing relapse in
|
| recurrent non-infectious uveitis affecting posterior segment of the eye. It is recommended only if the |
company provides it according to the commercial arrangement.
|
| RED Fluocinolone acetonide intravitreal implant (Iluvien®) NHS England Commissioned |
| |
| Dexamethasone intravitreal implant 700mcg [Ozurdex®] |
| Approved as second line treatment when there is no significant effectiveness and response of the diabetic macular |
| oedema to previous Anti VEGF |
| |
RED Dexamethasone intravitreal implant 700mcg (specialist use only) [Ozurdex®]
|
| CCG Commissioned Blueteq form required |
11.4.2 Other anti-inflammatory preparations
|
| Used to treat inflammation and allergic conjunctivitis |
| GREEN Sodium cromoglicate eye drops 2% (1st line option) |
| GREEN Otrivine-Antistin® eye drops |
| |
| Seasonal Allergic Conjunctivitis |
| GREEN Olopatadine eye drops 1mg/ml [maximum use 4 months] |
| restricted |
| (Consultant initiation only. 2nd line option, when first line of management fails or not adequate |
GREEN Ketotifen UDV eye drops 0.25mg/ml PF [Ketofall®]
|
restricted (option when preservative free product is required)
|
| |
| BACK to main chapter |
